# Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)

> **NCT01555138** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 581 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Indacaterol
- **DRUG:** Salmeterol

## Key facts

- **NCT ID:** NCT01555138
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 581 (ACTUAL)
- **Last updated:** 2015-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01555138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01555138, "Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01555138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*